Top 46 medical and healthcare startups in China

Dec 22, 2025
|
1
D3 Bio
Funding: $370M
D3 Bio specializes in the development of innovative immunotherapies in oncology and immunology. The company's lead drug, elisrasib, is a next-generation KRAS G12C inhibitor that is being studied as a potential monotherapy for non-small cell lung cancer and metastatic colorectal cancer, as well as in combination with Merck KGaA's Erbitux anticancer drug or with immune checkpoint inhibitors. The company's pipeline includes clinical trials against mut cancers, CRC, PanCa, breast cancer, gastric cancer, bladder cancer and other solid tumors.
2
WeDoctor
Funding: $1.5B
WeDoctor Group is an online healthcare service provider through its mobile apps and Guahao online portal
3
Abogen Biosciences
Funding: $1.4B
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics.
4
MediTrust Health
Funding: $920.3M
MediTrust Health is a leading medical innovation payment service brand in China.
5
Rakuten Aspyrian
Funding: $737.6M
Rakuten Aspyrian is developing tumor-targeted precision therapies based on its proprietary platform Photoimmunotherapy.
6
DXY
Funding: $682M
DXY is an online healthcare community for doctors, consumers, and healthcare organizations.
7
Waterdrop
Funding: $631.7M
Waterdrop is an online insurance technology platform that plans to solve the problem of high medical fees faced by many patients.
8
Ascentage Pharma
Funding: $504.7M
Ascentage Pharma is a China-based, global-oriented, clinical-stage biopharmaceutical company, dedicated to discovery and development of the “first-in-class” and the “best-in-class” targeted small-molecule cancer therapeutics.
9
Clover Biopharmaceuticals
Funding: $343.7M
Clover Biopharmaceuticals is a clinical-stage biotechnology company focused on developing novel and transformative biologic therapies.
10
Harbour BioMed
Funding: $312.8M
Harbour BioMed is a global biopharmaceutical company developing innovative therapeutics in the field of immuno-oncology and inflammatory diseases.
11
CanSinoBIO
Funding: $288.8M
Tianjin CanSino Biotech is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet medical needs by developing and marketing leading-edge, high quality vaccines for China and other emerging markets at affordable prices.
12
Angitia Biopharmaceuticals
Funding: $276M
Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics.
13
Chunyu Yisheng
Funding: $272.9M
Chinese smartphone app that lets users remotely consult with physicians to diagnose their ailments
14
Dingdang Health
Funding: $220M
Dingdang Health’s online-to-offline model enables it to supply drugs from the pharma manufacturers and offline pharmacies to meet users’ urgent medical needs.
15
Infervision
Funding: $214.7M
Beijing Infervision is an artificial intelligence high-tech company committed to applying deep learning technology to assist medical image diagnosis as efficient and accurate solutions. Infervision effectively uses various types of medical data to create clinically valued products and promotes precision analysis in the medical field especially in assisted image diagnosis.
16
iCarbonX
Funding: $200M
iCarbonX aims to build an ecosystem of digital life based on a combination of an individual’s biological, behavioral and psychological data, the Internet and artificial intelligence.
17
Connect Biopharma
Funding: $195M
Connect Biopharmaceuticals is a developer of novel immune modulators for the treatment of serious autoimmune diseases and inflammation.
18
JW Therapeutics
Funding: $190M
JW is focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer.
19
EdiGene
Funding: $179.7M
EdiGene is a biotechnology company that develops genome editing technologies.
20
Adagene
Funding: $180M
Adagene is an anticancer antibody discovery and engineering company which seeks to establish technology-driven discovery partnerships.
Editor: Jason Kwon
Jason Kwon is a senior editor for MedicalStartups. He has previously covered the pharmaceutical and medical research industries for FDAnews and worked as a head of marketing for medical startup Sonic Therapeutics. Before that, he co-founded a startup consulting business for emerging entrepreneurial hubs in Asia. Jason graduated from St. Bonaventure University’s journalism school. In his free time, Jason enjoys yoga, watching movie trailers, traveling to places where he can't get cell service. You can contact Jason at jaskwon(at)medicalstartups(dot)com